BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1581 related articles for article (PubMed ID: 27626136)

  • 21. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
    BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary cryotherapy for localised or locally advanced prostate cancer.
    Jung JH; Risk MC; Goldfarb R; Reddy B; Coles B; Dahm P
    Cochrane Database Syst Rev; 2018 May; 5(5):CD005010. PubMed ID: 29845595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    Wilt TJ; Vo TN; Langsetmo L; Dahm P; Wheeler T; Aronson WJ; Cooperberg MR; Taylor BC; Brawer MK
    Eur Urol; 2020 Jun; 77(6):713-724. PubMed ID: 32089359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.
    Abdel-Rahman O
    Clin Transl Oncol; 2019 Dec; 21(12):1673-1679. PubMed ID: 30929179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
    von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
    World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical prostatectomy versus watchful waiting in early prostate cancer.
    Bill-Axelson A; Holmberg L; Ruutu M; Garmo H; Stark JR; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Steineck G; Adami HO; Johansson JE;
    N Engl J Med; 2011 May; 364(18):1708-17. PubMed ID: 21542742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
    Rosenberg JE; Jung JH; Edgerton Z; Lee H; Lee S; Bakker CJ; Dahm P
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013641. PubMed ID: 32813279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical prostatectomy versus watchful waiting in early prostate cancer.
    Bill-Axelson A; Holmberg L; Ruutu M; Häggman M; Andersson SO; Bratell S; Spångberg A; Busch C; Nordling S; Garmo H; Palmgren J; Adami HO; Norlén BJ; Johansson JE;
    N Engl J Med; 2005 May; 352(19):1977-84. PubMed ID: 15888698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.